We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Mesenchymal Stem Cells Used as Drug Carrier

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mesenchymal Stem Cells Used as Drug Carrier "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

In a study published in the journal PLoS ONE and conducted by Augusto Pessina of the Department of Public Health, Microbiology and Virology of Milan University and Giulio Alessandri of the Cellular Neurobiology Laboratory, directed by Eugenio Parati of the Carlo Besta Neurological Institute of Milan, and Catholic University Sacro Cuore it has been demonstrated, for the first time, that human mesenchymal stem cells from bone marrow can be loaded “in vitro” with chemotherapeutic drugs and then used to treat tumors with high efficacy. These cells represent a new pharmacological device ( CellPharm®), patented by Besta Institute .

The device can be prepared by simple and economical procedures without genetic manipulation. In this way, it avoids related risk while providing more specific therapies with minor collateral effects. Importantly, the biological character ( to be drug loaded) of this new discovery seems to be shared by other cell populations ( such as fibroblasts, dendritic cells, monocytes and macrophages) present in blood and easy to isolate from patients.

The possibility to use cells from bone marrow, adipose or other tissues from the patient-donor (autologous use) eliminates immunological risk and also reduces the danger of pathogen agents transmission. The experimental demonstration of the efficacy of the method has been reported in tumors, but it can be applied to target other pathologies that require increasing drug delivery in specific tissues or organs.

The confirmation that the CellPharm® device maintains its therapeutic function even after storage in liquid nitrogen suggests its possible “banking”. The drug loaded cells could be used, for the same patient-donor, even a long time after their preparation ( eg: in the case of recidive).